- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01058694
The Impact of Short Message Services (SMS) on ARV Adherence in Western Kenya (CAPS)
Adherence to ARV Treatment and Its Effects on Medium Run Socio-Economic Outcomes: Evidence From Western Kenya
The purpose of proposed research is to implement a randomized study that will allow us to understand and address a number of key barriers to patient adherence as well as study the effects of better adherence on health and socio-economic outcomes.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Several studies have shown that proper adherence to treatment regimens is essential for the effectiveness of ARV therapy (e.g Wools-Kaloustian et al. 2006). There is also evidence in that in some treatment programs in Africa, adherence rates are not always high (Gill et al. 2005). Even in settings where adherence levels are found to be high, numerous factors have been identified as being relevant, although the causal effects are unknown (Castro, 2006). As ARV treatment programs are scaled up in Africa, it is essential to understand the socio-economic determinants of adherence to ARV treatment, as well as the impact of interventions to support high levels of adherence. A secondary objective of this study is to understand the socio-economic impacts of higher adherence.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Maseno District
-
Kisumu, Maseno District, Kenya
- Chulaimbo Rural Health Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients who had been on ARV therapy at the Chulaimbo Rural Health Center for a maximum of three months and providing consent to participate in the study.
Exclusion Criteria:
- Patients who had been on ARV therapy for more than 3 months.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation factorielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Weekly SMS, brief message
Weekly SMS received on Monday at 12 noon |
Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design. |
|
Comparateur actif: Control Group
Receives a phone, but no messages. |
Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design. |
|
Expérimental: Daily SMS, Brief message
Receive daily brief message at 12 noon: "This is your reminder" |
Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design. |
|
Expérimental: Daily SMS, Long Message
Receive a daily long message at 12 noon: "This is your reminder + encouragement" |
Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design. |
|
Expérimental: Weekly SMS, Long Message
Weekly message sent at 12 noon on Mondays: "This is your reminder + encouragement" |
Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
MEMS Adherence
Délai: 12 months follow up
|
12 months follow up
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Frequency/incidence of ARV treatment interruptions
Délai: 12 months follow up
|
12 months follow up
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: John Sidle, MD, Indiana University
- Chercheur principal: Duncan Ngare, Phd, Moi University
- Chercheur principal: Harsha Thirumurthy, Phd, University of North Carolina
- Chercheur principal: Markus Goldstein, Phd, World Bank
- Chercheur principal: Joshua Graff-Zivin, Phd, University of California, San Diego
- Chercheur principal: Cristian Pop-Eleches, Phd, Columbia University
- Chercheur principal: David Bangsberg, MD, Harvard Medical School (HMS and HSDM)
- Chercheur principal: Damien de Walque, Phd, World Bank
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Infections transmissibles par le sang
- Maladies urogénitales
- Maladies génitales
- Maladies du système immunitaire
- Infections
- Infections par virus à ARN
- Maladies virales
- Maladies transmissibles
- Maladies sexuellement transmissibles, virales
- Maladies sexuellement transmissibles
- Infections à lentivirus
- Infections à rétroviridae
- Syndromes d'immunodéficience
- Maladies à virus lents
- Comportement
- Adhésion et conformité au traitement
- Comportement de santé
- L'observance du patient
- Acceptation des soins de santé par le patient
- Infections à VIH
- Syndrome immunodéficitaire acquis
- Adhésion aux médicaments
Autres numéros d'identification d'étude
- 2008-005
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .